Tempus xF+
523-gene plasma liquid-biopsy comprehensive genomic profiling assay for therapy selection and molecular profiling in advanced cancer.
- Developer
- Tempus AI
- Intended use
- Other
- Cancer scope
- Not reported
- Specimen
- Peripheral whole blood
- Molecular modality
- DNA mutation
- Current version
- Tempus xF+ current 523-gene configuration (2026)
- Evidence context
- 1 structured studies · 0 indexed performance results · 1 sources
Why can reported performance numbers differ? MDI keeps each result attached to its study, population, stage or stratum, test version and source rather than treating performance as a fixed property of the test.